A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
News|Slideshows|January 29, 2024
IJMSC: January/February 2024 Highlights
Author(s)Erin E Gyomber
Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.
Advertisement
The International Journal of MS Care is a peer-reviewed, multidisciplinary, open access journal and the official journal of the Consortium of MS Centers. The journal strives to be useful and pertinent to all who are part of an MS care team, including physicians, nurses, therapists, and more.
As part of NeurologyLive's ongoing partnership with the CMSC, we're happy to spotlight some of the latest peer-reviewed articles published in IJMSC.
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
A new case report underscored the need to consider CNS lymphoproliferative disease when patients on chronic immunosuppression for neuromyelitis optica spectrum disorder develop unexplained neurologic decline.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease.
Here's some of what is coming soon to NeurologyLive® this week.
In honor of Muscular Dystrophy Awareness Month, held annually in September, NeurologyLive® looks back at the decade-long expansion of the DMD treatment landscape and the data that supports each approval.
Marketed as Fayuvi, the 1-time AAV9 gene therapy showed sustained cerebrospinal fluid heparan sulfate drops and developmental gains among pediatric patients with mucopolysaccharidosis type IIIA in prior studies.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring the Unmet Needs in CIDP
2
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
3
Previewing Advancements in Hypersomnia Diagnosis and Treatment
4
RIPK1 Inhibitor Fails to Slow Functional Decline in Phase 2 ALS Trial
5